BACKGROUND: The impact of early adequate empirical antibiotic therapy on outcomes of infants in the neonatal intensive care unit (NICU) who develop Staphylococcus aureus bloodstream infections (BSI) is unknown. METHODS: Infants with S. aureus BSI discharged in 1997-2012 from 348 NICUs managed by the Pediatrix Medical Group were identified. Early adequate empirical antibiotic therapy was defined as exposure to ≥1 antibiotic with anti-staphylococcal activity on the day the first positive blood culture was obtained. All other cases were defined as inadequate empirical antibiotic therapy. We evaluated the association between inadequate empirical antibiotic therapy on outcomes controlling for gestational age, small for gestational age status, gender, discharge year, mechanical ventilation, inotropic support and use of supplemental oxygen. The primary outcome was 30-day mortality. Secondary outcomes were 7-day mortality, death before hospital discharge and length of bacteremia. RESULTS: Of the 3339 infants with S. aureus BSI, 2492 (75%) had methicillin-susceptible S. aureus (MSSA) BSI and 847 (25%) had methicillin-resistant S. aureus (MRSA) BSI. Inadequate empirical antibiotic therapy was administered in 725 (22%) cases. Inadequate empirical antibiotic therapy was associated with increased 30-day mortality (odds ratio: 2.03; 95% confidence interval: 1.08-3.82) among infants with MRSA BSI. Inadequate empirical antibiotic therapy was not associated with increases in mortality among infants with MSSA BSI. CONCLUSIONS: After controlling for confounders, inadequate empirical antibiotic therapy was associated with a modestly increased mortality at 30 days for infants with MRSA BSI.
BACKGROUND: The impact of early adequate empirical antibiotic therapy on outcomes of infants in the neonatal intensive care unit (NICU) who develop Staphylococcus aureus bloodstream infections (BSI) is unknown. METHODS: Infants with S. aureus BSI discharged in 1997-2012 from 348 NICUs managed by the Pediatrix Medical Group were identified. Early adequate empirical antibiotic therapy was defined as exposure to ≥1 antibiotic with anti-staphylococcal activity on the day the first positive blood culture was obtained. All other cases were defined as inadequate empirical antibiotic therapy. We evaluated the association between inadequate empirical antibiotic therapy on outcomes controlling for gestational age, small for gestational age status, gender, discharge year, mechanical ventilation, inotropic support and use of supplemental oxygen. The primary outcome was 30-day mortality. Secondary outcomes were 7-day mortality, death before hospital discharge and length of bacteremia. RESULTS: Of the 3339 infants with S. aureus BSI, 2492 (75%) had methicillin-susceptible S. aureus (MSSA) BSI and 847 (25%) had methicillin-resistant S. aureus (MRSA) BSI. Inadequate empirical antibiotic therapy was administered in 725 (22%) cases. Inadequate empirical antibiotic therapy was associated with increased 30-day mortality (odds ratio: 2.03; 95% confidence interval: 1.08-3.82) among infants with MRSA BSI. Inadequate empirical antibiotic therapy was not associated with increases in mortality among infants with MSSA BSI. CONCLUSIONS: After controlling for confounders, inadequate empirical antibiotic therapy was associated with a modestly increased mortality at 30 days for infants with MRSA BSI.
Authors: A Soriano; J A Martínez; J Mensa; F Marco; M Almela; A Moreno-Martínez; F Sánchez; I Muñoz; M T Jiménez de Anta; E Soriano Journal: Clin Infect Dis Date: 2000-02 Impact factor: 9.079
Authors: R Scott Watson; Joseph A Carcillo; Walter T Linde-Zwirble; Gilles Clermont; Jeffrey Lidicker; Derek C Angus Journal: Am J Respir Crit Care Med Date: 2002-11-14 Impact factor: 21.405
Authors: Barbara J Stoll; Nellie Hansen; Avroy A Fanaroff; Linda L Wright; Waldemar A Carlo; Richard A Ehrenkranz; James A Lemons; Edward F Donovan; Ann R Stark; Jon E Tyson; William Oh; Charles R Bauer; Sheldon B Korones; Seetha Shankaran; Abbot R Laptook; David K Stevenson; Lu-Ann Papile; W Kenneth Poole Journal: Pediatrics Date: 2002-08 Impact factor: 7.124
Authors: Heiman F L Wertheim; Margreet C Vos; Alewijn Ott; Alex van Belkum; Andreas Voss; Jan A J W Kluytmans; Peter H J van Keulen; Christina M J E Vandenbroucke-Grauls; Marlene H M Meester; Henri A Verbrugh Journal: Lancet Date: 2004 Aug 21-27 Impact factor: 79.321
Authors: Feng-Yee Chang; James E Peacock; Daniel M Musher; Patricia Triplett; Brent B MacDonald; Joseph M Mylotte; Alice O'Donnell; Marilyn M Wagener; Victor L Yu Journal: Medicine (Baltimore) Date: 2003-09 Impact factor: 1.889
Authors: Sarah B Doernberg; Thomas P Lodise; Joshua T Thaden; Jose M Munita; Sara E Cosgrove; Cesar A Arias; Helen W Boucher; G Ralph Corey; Franklin D Lowy; Barbara Murray; Loren G Miller; Thomas L Holland Journal: Clin Infect Dis Date: 2017-03-15 Impact factor: 9.079